Brokerages predict that American Renal Associates Holdings Inc (NYSE:ARA) will report $0.01 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for American Renal Associates’ earnings. American Renal Associates posted earnings per share of $0.11 in the same quarter last year, which would suggest a negative year over year growth rate of 90.9%. The business is expected to announce its next earnings report on Tuesday, May 14th.
On average, analysts expect that American Renal Associates will report full-year earnings of $0.34 per share for the current year. For the next fiscal year, analysts anticipate that the company will post earnings of $0.39 per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow American Renal Associates.
ARA has been the subject of several recent analyst reports. Zacks Investment Research cut shares of American Renal Associates from a “buy” rating to a “hold” rating in a report on Wednesday, February 20th. SunTrust Banks reiterated a “buy” rating and issued a $16.00 target price on shares of American Renal Associates in a report on Wednesday, January 9th. Leerink Swann cut shares of American Renal Associates to a “market perform” rating in a report on Monday, March 11th. Deutsche Bank initiated coverage on shares of American Renal Associates in a report on Thursday, January 3rd. They issued a “hold” rating and a $12.00 target price for the company. Finally, Barclays set a $9.00 target price on shares of American Renal Associates and gave the stock a “hold” rating in a report on Thursday, March 28th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $15.92.
Several hedge funds have recently bought and sold shares of ARA. Foresters Investment Management Company Inc. acquired a new stake in shares of American Renal Associates during the fourth quarter worth approximately $3,822,000. Dimensional Fund Advisors LP boosted its holdings in shares of American Renal Associates by 39.2% during the third quarter. Dimensional Fund Advisors LP now owns 690,103 shares of the company’s stock worth $14,941,000 after purchasing an additional 194,395 shares during the period. BlackRock Inc. boosted its holdings in shares of American Renal Associates by 17.1% during the third quarter. BlackRock Inc. now owns 955,892 shares of the company’s stock worth $20,693,000 after purchasing an additional 139,789 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of American Renal Associates by 31.7% during the third quarter. Renaissance Technologies LLC now owns 457,800 shares of the company’s stock worth $9,911,000 after purchasing an additional 110,300 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of American Renal Associates by 28.1% during the fourth quarter. Geode Capital Management LLC now owns 205,509 shares of the company’s stock worth $2,366,000 after purchasing an additional 45,142 shares during the period. Institutional investors and hedge funds own 95.34% of the company’s stock.
American Renal Associates Company Profile
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.
Featured Article: Balance Sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.